Skip to content

UW/Kaiser study finds taking Proton Pump Inhibitors not linked to higher dementia risk

Proton pump inhibitors (PPIs) are medicines commonly prescribed to treat acid-related digestive problems, including gastroesophageal reflux disease.  Up to one in five older adults said they used a PPI as of 2011, and recent studies have linked PPIs to greater risk of fractures and kidney disease. Some studies also have linked PPIs to an increased risk for dementia among older adults, though several experts have questioned whether these studies correctly measured the connection.

Research (PDF) published today in the Journal of the American Geriatrics Society appears to challenge those earlier findings.

Plein Center Director and Bridge Endowed Professor Shelly Gray opened the Plein Symposium
Plein Center Director and Bridge Endowed Professor Shelly Gray opened the Plein Symposium

University of Washington School of Pharmacy Plein Center for Geriatric Pharmacy Director and Shirley & Herb Bridge Endowed Professor Shelly Gray, along with other researchers at the University of Washington School of Pharmacy and Kaiser Permanente Washington Research Institute, reviewed information from the joint UW-Kaiser Permanente Adult Changes in Thought (ACT) study, which included 3,484 subjects 65 and older. Information from the electronic pharmacy records was used to see how many participants took PPIs, and for how long.

Overall, nearly one in four participants developed dementia, including 670  with possible or probable Alzheimer’s disease.  People with the heaviest use of PPIs – equivalent to five years of daily use at typical doses – did not have a higher risk of developing dementia than those with no PPI use.

“While some other safety concerns with long-term PPI use might be real, results from our study suggest that dementia is not linked to taking a PPI.” –Shelly Gray, corresponding author and UW School of Pharmacy professor

To interview Shelly Gray, email UW Medicine Media Relations:

* * *

This summary is from “Proton Pump Inhibitor Use and Dementia Risk: Prospective Population Based Study.” It appears online ahead of print in the Journal of the American Geriatrics Society. The study authors are Shelly L. Gray, PharmD, MS; Rod L. Walker, MS; Sascha Dublin, MD, PhD; Onchee Yu, MS; Erin J. Aiello Bowles, MPH; Melissa L. Anderson, MS; Paul K. Crane, MD, MPH; and Eric B. Larson, MD, MPH.


Are you interested in working with the top-rated faculty and studying pharmacy with preeminent student peers?

Click here for more information about the Plein Geriatric Pharmacy Certificate or click these links to learn about the UW PharmD program or thePharmaceutical Outcomes Research and Policy Program.